MedDataX Logo

Explanted Lung Tissues With Pulmonary Fibrosis

NCT ID: NCT00515567

Last Updated: 2026-01-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

90 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-02-28

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to use the tissues from the explanted lungs in order to better study the cause of pulmonary fibrosis at a cellular level.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analysis of Specimens From Individuals With Pulmonary Fibrosis

NCT00084305

Pulmonary Fibrosis Healthy Volunteers Hermansky-Pudlak Syndrome (HPS)
ACTIVE_NOT_RECRUITING

Tissue Collection From People With Cystic Fibrosis

NCT00015756

Cystic Fibrosis
COMPLETED

Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis

NCT04262167

Idiopathic Pulmonary Fibrosis and Progressive Fibrotic Interstitial Lung Disease
ACTIVE_NOT_RECRUITING PHASE1

Idiopathic Pulmonary Fibrosis: a Case-control Study

NCT00005295

Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial
TERMINATED

Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients

NCT05899556

Pulmonary Fibrosis
NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pulmonary Fibrosis involves scarring of the lung. Gradually, the air sacs of the lungs become replaced by fibrotic tissue. The most current thinking is that the fibrotic process is a reaction to tiny injury to the lung. When the scar forms, the tissue becomes thicker causing a permanent loss of the tissue's ability to carry oxygen into the bloodstream.

We need to obtain lung tissue from patients without pulmonary fibrosis and compare it to lung tissue from patients with pulmonary fibrosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* all patients awaiting lung transplant

Exclusion Criteria

* all who will not give consent
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Chicago

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nickolai Dulin, MD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Chicago

Chicago, Illinois, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nickolai Dulin, MD

Role: CONTACT

[email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Janine Grohar

Role: primary

[email protected]
773-702-6156

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

14514A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tissue Bank for Pulmonary Diseases
NCT00546962 UNKNOWN
GEN-FPF: Genetic Exploration of Familial Pulmonary Fibrosis
NCT07251725 RECRUITING
Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations
NCT02606487 COMPLETED
Molecular Phenotypes for Cystic Fibrosis Lung Disease
NCT01116414 COMPLETED
18FDG-PET Imaging to Detect Changes in Airways Inflammation in Cystic Fibrosis Patients
NCT00684346 COMPLETED PHASE3
Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF
NCT02109822 COMPLETED
Early Intervention in Pulmonary Exacerbation in Cystic Fibrosis
NCT00850551 COMPLETED NA
Cystic Fibrosis (CF) Leukocyte Genes as Biomarkers for Novel Therapies
NCT00727285 COMPLETED
19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation
NCT03497117 TERMINATED EARLY_PHASE1
Tracking CF Lung Disease Through the Early Years: Utility of the LCI
NCT03138772 COMPLETED
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
NCT00581997 TERMINATED PHASE2
Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung
NCT01805713 COMPLETED
Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation in CF
NCT02464267 COMPLETED
Quantification of Pulmonary Neutrophil Activity in Cystic Fibrosis Using Radiolabeled Fluorodeoxyglucose and PET Imaging
NCT00023465 UNKNOWN
Exocrine Pancreatic Function Testing in Cystic Fibrosis
NCT01446861 UNKNOWN
A Study to Investigate Cystic Fibrosis Pulmonary Exacerbations and the Lung Microbiome
NCT05088447 TERMINATED
Early Intervention in Cystic Fibrosis Exacerbation
NCT01104402 COMPLETED NA
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
NCT01851642 RECRUITING
Lung Transplantation for Pleuroparenchymal Fibroelastosis
NCT05044390 UNKNOWN
Biodistribution of Neutrophile Proteases in the Sputum of Patients Affected by Cystic Fibrosis
NCT00750932 COMPLETED
Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT06506773 COMPLETED
Cystic Fibrosis and Frailtyh What's in Common?
NCT06020547 COMPLETED
CAR-DC for End-Stage IPF
NCT07329959 NOT_YET_RECRUITING PHASE1
Platelets in Cystic Fibrosis Lung Inflammation
NCT05339724 COMPLETED
MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia
NCT03279965 UNKNOWN